BR112013005438A2 - "agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo." - Google Patents
"agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo."Info
- Publication number
- BR112013005438A2 BR112013005438A2 BR112013005438A BR112013005438A BR112013005438A2 BR 112013005438 A2 BR112013005438 A2 BR 112013005438A2 BR 112013005438 A BR112013005438 A BR 112013005438A BR 112013005438 A BR112013005438 A BR 112013005438A BR 112013005438 A2 BR112013005438 A2 BR 112013005438A2
- Authority
- BR
- Brazil
- Prior art keywords
- salt
- hyaluronic acid
- dry eye
- receptor agonist
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y y~ 2~ e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y y~ 2~ e ácido hialurônico ou um sal do mesmo. a presente invenção refere-se a um agente para o tratamento de olho ressecado compreendendo uma combinação de um agonista do receptor de p2y y ~2 ~ em uma concentração terapeuticamente eficaz e ácido hialurônico ou um sal do mesmo em uma concentração terapeuticamente eficaz, agente este que tem uma forma de dosagem de um agente oftálmico, pode promover a secreção acentuada de lágrimas e pode melhorar acentuadamente distúrbios epiteliais da córnea, e portanto espera-se que este seja um novo agente para o tratamento de olho ressecado.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010203198 | 2010-09-10 | ||
| JP2010-203198 | 2010-09-10 | ||
| PCT/JP2011/070578 WO2012033189A1 (ja) | 2010-09-10 | 2011-09-09 | Ｐ２ｙ2受容体作動薬およびヒアルロン酸またはその塩を組み合わせたことを特徴とするドライアイ治療剤、ドライアイの治療方法、ならびにその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013005438A2 true BR112013005438A2 (pt) | 2016-05-17 |
| BR112013005438B1 BR112013005438B1 (pt) | 2021-09-21 |
Family
ID=45810785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013005438-7A BR112013005438B1 (pt) | 2010-09-10 | 2011-09-09 | Agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9006208B2 (pt) |
| EP (1) | EP2614838B1 (pt) |
| JP (1) | JP5956735B2 (pt) |
| KR (2) | KR20170018462A (pt) |
| CN (2) | CN106729718A (pt) |
| AU (2) | AU2011299851A1 (pt) |
| BR (1) | BR112013005438B1 (pt) |
| CA (1) | CA2810481C (pt) |
| DK (1) | DK2614838T3 (pt) |
| EA (1) | EA026680B1 (pt) |
| ES (1) | ES2569246T3 (pt) |
| HK (1) | HK1184686A1 (pt) |
| MX (1) | MX336944B (pt) |
| MY (1) | MY170198A (pt) |
| NZ (1) | NZ608202A (pt) |
| PL (1) | PL2614838T3 (pt) |
| SG (1) | SG188482A1 (pt) |
| TW (1) | TWI519301B (pt) |
| WO (1) | WO2012033189A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012090994A1 (ja) * | 2010-12-28 | 2012-07-05 | 参天製薬株式会社 | ジクアホソル含有点眼液およびその製造方法、不溶性析出物発生の抑制方法 |
| US9486529B2 (en) | 2012-03-26 | 2016-11-08 | Santen Pharmceutical Co., Ltd. | Ophthalmic solution comprising diquafosol |
| US9492474B2 (en) | 2013-07-10 | 2016-11-15 | Matrix Biology Institute | Compositions of hyaluronan with high elasticity and uses thereof |
| US9289494B2 (en) | 2013-11-20 | 2016-03-22 | RestorTears, LLC | Method of treating ocular disorders with compounds found in Harderian gland secretions |
| JP6267003B2 (ja) * | 2014-02-27 | 2018-01-24 | 参天製薬株式会社 | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 |
| JP2017002035A (ja) * | 2015-06-05 | 2017-01-05 | 参天製薬株式会社 | ソフトコンタクトレンズが装用されたドライアイ患者の眼に点眼されるように用いられることを特徴とするドライアイ治療剤 |
| JP2017052723A (ja) * | 2015-09-10 | 2017-03-16 | 株式会社Ｌｔｔバイオファーマ | ドライアイ改善剤 |
| PT3352766T (pt) | 2015-09-24 | 2022-03-22 | Matrix Biology Inst | Composições de hialuronano de elevada elasticidade e processos para o seu uso |
| KR20190068575A (ko) * | 2016-10-14 | 2019-06-18 | 이콤 메디칼 게엠베하 | 안구 표면 항상성의 확립, 회복 및 보존 방법 |
| KR20190071674A (ko) | 2016-10-21 | 2019-06-24 | 라이온 가부시키가이샤 | 안과용 제제 및 안과용 약 |
| CN107096016B (zh) * | 2017-06-26 | 2021-04-06 | 蒋广伟 | 一种缓解视力疲劳的滴液 |
| RU2652581C1 (ru) * | 2017-07-03 | 2018-04-26 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения роговично-конъюнктивального ксероза |
| KR102108552B1 (ko) * | 2018-05-15 | 2020-05-08 | 한국세라믹기술원 | 히알루론산 마이크로비드의 제조 방법 및 상기 히알루론산 마이크로비드의 용도 |
| CN109260146A (zh) * | 2018-10-12 | 2019-01-25 | 广州大光制药有限公司 | 地夸磷索钠眼用即用型凝胶滴眼液及制备方法 |
| JPWO2020175525A1 (ja) | 2019-02-27 | 2021-12-23 | 参天製薬株式会社 | ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物 |
| JP6966667B2 (ja) * | 2019-08-27 | 2021-11-17 | 参天製薬株式会社 | ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01115902A (ja) | 1987-10-30 | 1989-05-09 | Showa Sangyo Co Ltd | ヒアルロン酸の製造法 |
| US5900407A (en) | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| CN1262556C (zh) | 1997-02-06 | 2006-07-05 | 印斯拜尔药品股份有限公司 | 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用 |
| US7223744B2 (en) | 1997-02-10 | 2007-05-29 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof |
| DK1012154T3 (da) | 1997-07-25 | 2004-07-26 | Inspire Pharmaceuticals Inc | Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf |
| JP2003160491A (ja) | 2001-09-11 | 2003-06-03 | Santen Pharmaceut Co Ltd | ジウリジンリン酸含有点眼液 |
-
2011
- 2011-09-09 PL PL11823663.7T patent/PL2614838T3/pl unknown
- 2011-09-09 JP JP2011197020A patent/JP5956735B2/ja active Active
- 2011-09-09 EA EA201390364A patent/EA026680B1/ru not_active IP Right Cessation
- 2011-09-09 CN CN201611152170.7A patent/CN106729718A/zh active Pending
- 2011-09-09 MX MX2013002677A patent/MX336944B/es active IP Right Grant
- 2011-09-09 EP EP11823663.7A patent/EP2614838B1/en active Active
- 2011-09-09 DK DK11823663.7T patent/DK2614838T3/en active
- 2011-09-09 US US13/821,717 patent/US9006208B2/en not_active Expired - Fee Related
- 2011-09-09 AU AU2011299851A patent/AU2011299851A1/en not_active Abandoned
- 2011-09-09 BR BR112013005438-7A patent/BR112013005438B1/pt not_active IP Right Cessation
- 2011-09-09 WO PCT/JP2011/070578 patent/WO2012033189A1/ja active Application Filing
- 2011-09-09 KR KR1020177003213A patent/KR20170018462A/ko not_active Application Discontinuation
- 2011-09-09 NZ NZ60820211A patent/NZ608202A/en not_active IP Right Cessation
- 2011-09-09 SG SG2013017652A patent/SG188482A1/en unknown
- 2011-09-09 KR KR1020137008451A patent/KR101707269B1/ko active IP Right Grant
- 2011-09-09 MY MYPI2013000810A patent/MY170198A/en unknown
- 2011-09-09 TW TW100132506A patent/TWI519301B/zh not_active IP Right Cessation
- 2011-09-09 CN CN2011800435775A patent/CN103096929A/zh active Pending
- 2011-09-09 ES ES11823663.7T patent/ES2569246T3/es active Active
- 2011-09-09 CA CA2810481A patent/CA2810481C/en not_active Expired - Fee Related
-
2013
- 2013-10-28 HK HK13112123.0A patent/HK1184686A1/zh not_active IP Right Cessation
-
2017
- 2017-02-07 AU AU2017200821A patent/AU2017200821B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170018462A (ko) | 2017-02-17 |
| TW201216971A (en) | 2012-05-01 |
| WO2012033189A1 (ja) | 2012-03-15 |
| CN106729718A (zh) | 2017-05-31 |
| EP2614838B1 (en) | 2016-04-20 |
| CA2810481A1 (en) | 2012-03-15 |
| MX336944B (es) | 2016-02-03 |
| KR101707269B1 (ko) | 2017-02-15 |
| US20130172287A1 (en) | 2013-07-04 |
| EA201390364A1 (ru) | 2013-08-30 |
| SG188482A1 (en) | 2013-04-30 |
| EP2614838A4 (en) | 2014-02-26 |
| AU2017200821A1 (en) | 2017-03-02 |
| DK2614838T3 (en) | 2016-05-02 |
| JP5956735B2 (ja) | 2016-07-27 |
| HK1184686A1 (zh) | 2014-01-30 |
| EP2614838A1 (en) | 2013-07-17 |
| BR112013005438B1 (pt) | 2021-09-21 |
| ES2569246T3 (es) | 2016-05-09 |
| JP2012077080A (ja) | 2012-04-19 |
| CN103096929A (zh) | 2013-05-08 |
| MX2013002677A (es) | 2013-06-13 |
| KR20130109130A (ko) | 2013-10-07 |
| EA026680B1 (ru) | 2017-05-31 |
| NZ608202A (en) | 2014-08-29 |
| MY170198A (en) | 2019-07-09 |
| AU2017200821B2 (en) | 2018-08-30 |
| AU2011299851A1 (en) | 2013-04-04 |
| US9006208B2 (en) | 2015-04-14 |
| CA2810481C (en) | 2018-06-19 |
| PL2614838T3 (pl) | 2016-10-31 |
| TWI519301B (zh) | 2016-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013005438A2 (pt) | "agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo." | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
| BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
| BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
| BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
| BR112015014260A2 (pt) | método para indicar o tempo para a lavagem ou indicar a distribuição de agente antibacteriano | |
| BR112013028907A2 (pt) | conjugados de proteína-agente ativo e método para preparar os mesmos | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| BR112015017997A2 (pt) | amidas de quinolina e quinazolina como moduladores de canais de sódio | |
| BR112015018284A2 (pt) | amidas como moduladores de canais de sódio | |
| BR112016006926A8 (pt) | uso de um conjugado de ácido quínico com pelo menos uma molécula de ácido cafeico na preparação de uma composição para a prevenção e/ou a melhora da senescência de célula ou tecido | |
| BR112014031204A2 (pt) | derivados deuterados de ruxolitinib | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112013019257A2 (pt) | composição de androgênio para tratar uma condição oftálmica | |
| BR112013031652A2 (pt) | métodos de tratamento para doenças retinais | |
| BR112014008036A2 (pt) | tratamento de rinite | |
| BR112014001118A2 (pt) | combinação tópica para aplicação oftálmica e uso de bimatoprost e brimonidina | |
| BR112013022094A2 (pt) | composições e métodos para o tratamento não cirúrgico da ptose | |
| BR112014006587A2 (pt) | modulação antisense da expressão de gcgr | |
| BR112013022213A2 (pt) | administração parenteral de tapentadol | |
| BR112014027884A2 (pt) | combinações farmacêuticas para tratamento de distúrbios metabólicos | |
| BR112013033831A2 (pt) | composição farmacêutica oftalmológica tópica que contém regorafenib | |
| BR112013033008A8 (pt) | composição farmacêutica líquida compreendendo nitisinona | |
| BR112014010729A2 (pt) | métodos para tratamento de ataques de gota |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2739 DE 04-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |